Eivor Hernes

Latest

• First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted 212Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer
• Added Value of [18F]PSMA-1007 PET/CT and PET/MRI in Patients With Biochemically Recurrent Prostate Cancer: Impact on Detection Rates and Clinical Management
• Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine
• Deep learning-based automatic delineation of anal cancer gross tumour volume: a multimodality comparison of CT, PET and MRI
• Localization of primary prostate cancer: FACBC PET/CT compared with multiparametric MRI using histopathology as reference standard
• Robotic salvage pelvic lymph node dissection for locoregional recurrence after radical prostatectomy: a single institution experience
• 18F-Fluciclovine PET for Assessment of Prostate Cancer with Histopathology as Reference Standard: A Systematic Review
• Prostate-Specific Membrane Antigen PET for Assessment of Primary and Recurrent Prostate Cancer with Histopathology as Reference Standard: A Systematic Review and Meta-Analysis
• Metastatic-directed therapy using PSMA-PET/CT at PSA relapse
• Anal cancer chemoradiotherapy outcome prediction using 18F-fluorodeoxyglucose positron emission tomography and clinicopathological factors
• Target volume delineation of anal cancer based on magnetic resonance imaging or positron emission tomography
• Dynamic 2-Deoxy-2-[18F]Fluoro-D-Glucose Positron Emission Tomography for Chemotherapy Response Monitoring of Breast Cancer Xenografts
• Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223
• Treatment and 5-year survival in patients with nonmetastatic prostate cancer: the Norwegian experience
• A national study of adverse effects and global quality of life among candidates for curative treatment for prostate cancer
• Fatigue in prostate cancer survivors treated with definitive radiotherapy and LHRH analogs
• Initial management of prostate cancer: first year experience with the Norwegian National Prostate Cancer Registry
• Re: E. David Crawford, Per-Anders Abrahamsson. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests? Eur Urol 2008;54:262-73
• Unreliable survival analysis
• High prostate cancer mortality in Norway evaluated by automated classification of medical entities
• Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries
• Treatment of hormone-resistant prostate cancer
• NY-ESO-1 protein expression and humoral immune responses in prostate cancer
• Androgen-independent prostate cancer--the clinical problem of a growing pelvic tumour